Initial Target Product Profile & Market Opportunity
Initial market opportunity
- DNA alkylating/binding agents characterized by dose-limiting toxicities are widely used in the target cancers, suggesting that a drug with a substantially wider therapeutic window would be a major advance
- Robust CT-262 preclinical data suggest CT-262 will be efficacious in the target cancers
- Blood brain barrier studies with CT-262 are being planned to evaluate the utility in treating glioblastoma
- DNA alkylating agents widely used in the treatment of glioblastoma
- Large unmet need continues to exist in the target cancers, suggesting the potential for both accelerated regulatory approval and rapid adoption by clinicians
- Primary differentiation: Potential wide therapeutic window and highly efficacious
Follow-on market opportunity
- Potential first-line therapy in multiple cancer indications
- Primary differentiation: Potential ability to add to existing treatment regimens, increasing efficacy without meaningfully increasing toxicity